Clinical Trials Logo

Clinical Trial Summary

Phase III multicentric, open-label, randomized study The main objective is to assess the efficacy on time to disease recurrence (TTR) of treating minimal residual disease diagnosed by the presence of ctDNA after full treatment (surgery + chemotherapy) in stage III or high-risk stage II colon or upper rectum adenocarcinoma


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06197425
Study type Interventional
Source Centre Hospitalier Universitaire Dijon
Contact Julien TAIEB
Phone 01 56 09 50 42
Email julien.taieb@egp.aphp.fr
Status Not yet recruiting
Phase Phase 3
Start date January 2024
Completion date January 2030